INSYS Therapeutics, Inc. (NASDAQ:INSY) reached 39.4% versus a 1-year low price of $3.35. The stock was last seen 4.01% higher, reaching at $4.67 on 01/11/2019. At recent session, the prices were hovering between $4.47 and $5.09. This company shares are 79.87% off its target price of $8.4 and the current market capitalization stands at $333.48M. The recent change has given its price a -20.04% deficit over SMA 50 and -59.91% deficit over its 52-week high. The stock witnessed -7.71% declines, -45.76% declines and -38.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found INSY’s volatility during a week at 8.45% and during a month it has been found around 9.51%.INSYS Therapeutics, Inc. (INSY) Top Holders
Institutional investors currently hold around $60 million or 22.2% in INSY stock. Look at its top three institutional owners. Orbimed Advisors Llc owns $14.14 million in INSYS Therapeutics, Inc., which represents roughly 4.24% of the company’s market cap and approximately 23.57% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,710,787 shares of the stock are valued at $12.66 million. The third largest holder is Vanguard Group Inc, which currently holds $12.43 million worth of this stock and that ownership represents nearly 3.73% of its market capitalization.INSYS Therapeutics, Inc. 13F Filings
At the end of September reporting period, 47 institutional holders increased their position in INSYS Therapeutics, Inc. (NASDAQ:INSY) by some 1,073,089 shares, 36 decreased positions by 1,713,066 and 36 held positions by 10,031,335. That puts total institutional holdings at 12,817,490 shares, according to SEC filings. The stock grabbed 18 new institutional investments totaling 231,058 shares while 11 institutional investors sold out their entire positions totaling 973,107 shares.INSYS Therapeutics, Inc. (NASDAQ:INSY) Insider Trades
Multiple company employees have indulged in significant insider trading. INSYS Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Tambi Brian has sold 166,504 shares of INSYS Therapeutics, Inc. (INSY) in trading session dated May. 10, 2018. These shares are worth $1,067,291 and were traded at $6.41 each. The SEC filing shows that John N Kapoor Trust Dated Sept performed a purchase of 17,500 shares. The 10% Owner added these shares by way of transaction on Aug. 11, 2017. The company’s shares were assimilated at $8.93 per share worth to an investment of some $156,275 on account of John N Kapoor Trust Dated Sept.
President & CEO, Motahari Saeed, purchased 5,500 common shares of INSYS Therapeutics, Inc. (INSY) in the open market. In a transaction dated Aug. 10, 2017, the shares were bought at an average price of $8.92, giving away a sum of $49,060. After this purchase, 15,400 common shares of INSY are directly owned by the insider, with total stake valued at $71,918.
In the transaction dated Jun. 14, 2017, the great number of shares acquired came courtesy the President & CEO; Motahari Saeed added a total of 5,400 shares at an average price of $11.1, amounting to approximately $59,940. The insider now directly owns 9,900 shares worth $46,233.INSYS Therapeutics, Inc. (INSY) Analyst Guide
Several analysts have released their opinion on INSYS Therapeutics, Inc. (NASDAQ:INSY), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.